<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105153</url>
  </required_header>
  <id_info>
    <org_study_id>S-469/19</org_study_id>
    <secondary_id>ESR-19-14460</secondary_id>
    <nct_id>NCT04105153</nct_id>
  </id_info>
  <brief_title>Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC</brief_title>
  <official_title>Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thoraxklinik-Heidelberg gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thoraxklinik-Heidelberg gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor
      receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the
      majority of cases and a median overall survival currently exceeding 2.5 years. However,
      clinical courses vary widely and eventual treatment failure is inevitable. The most common
      resistance mechanism against first- and second-generation EGFR inhibitors is the EGFR T790M
      mutation, which emerges in about 50% of cases and is amenable to next-line treatment with the
      third-generation compound osimertinib. However, experience in everyday clinical practice
      shows that implementation of EGFR TKI sequencing is often problematic, for example because a
      considerable number of EGFR+ NSCLC patients failing first- and second-generation EGFR
      inhibitors do not undergo T790M mutation testing at the time of disease progression. This
      study will use patient records to analyze the clinical course of EGFR+ NSCLC patients treated
      with first- and second-generation EGFR inhibitors at the Thoraxklinik Heidelberg (Germany)
      during the past years. The main aim is to analyze the diagnostic and therapeutic measures,
      including implementation of osimertinib, taken at the time of disease progression as well as
      their effect on patient outcome in a real-world, routine clinical setting.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of EGFR+ NSCLC patients with sequential TKI treatment</measure>
    <time_frame>assessment will performed retrospectively for all study patients from September 2019 until June 2020</time_frame>
    <description>the rate of rebiopsy and molecular workup (especially T790M testing) at disease progression under treatment with first-/second-generation EGFR inhibitors
the frequency of T790M mutations in the molecular workup of patients with disease progression under first-/second-generation EGFR inhibitors
the actual rate of osimertinib implementation after failure of first-/second-generation EGFR inhibitors in the &quot;real-world&quot; setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>assessment will performed retrospectively for all study patients from September 2019 until June 2020</time_frame>
    <description>Progression-free survival (PFS) of patients treated with first-/second-generation EGFR inhibitors and/or osimertinib in the real-world setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-next-treatment (TNT)</measure>
    <time_frame>assessment will performed retrospectively for all study patients from September 2019 until June 2020</time_frame>
    <description>Time-to-next-treatment (TNT) of patients treated with first-/second-generation EGFR inhibitors and/or osimertinib in the real-world setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-chemotherapy (TTC)</measure>
    <time_frame>assessment will performed retrospectively for all study patients from September 2019 until June 2020</time_frame>
    <description>Time-to-chemotherapy (TTC) of patients treated with first-/second-generation EGFR inhibitors and/or osimertinib in the real-world setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>assessment will performed retrospectively for all study patients from September 2019 until June 2020</time_frame>
    <description>Overall survival (OS) of patients treated with first-/second-generation EGFR inhibitors and/or osimertinib in the real-world setting</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>EGFR Positive Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TKI-treated advanced EGFR+ NSCLC</arm_group_label>
    <description>Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All NSCLC patients with activating EGFR mutations treated with EGFR TKI at the Thoraxklinik
        Heidelberg between 2010 and 2019.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed locally advanced (stage III) and not suitable for definitive
             local treatment, or metastatic (stage IV) NSCLC

          -  activating EGFR mutation confirmed

          -  treatment with EGFR TKI

        Exclusion Criteria:

        none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petros Christopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.</citation>
    <PMID>27959700</PMID>
  </reference>
  <reference>
    <citation>Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, Kuckovic A, Singh S, Miller RJ, Puri N. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers (Basel). 2018 Jul 4;10(7). pii: E224. doi: 10.3390/cancers10070224. Review.</citation>
    <PMID>29973561</PMID>
  </reference>
  <reference>
    <citation>Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.</citation>
    <PMID>23816960</PMID>
  </reference>
  <reference>
    <citation>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.</citation>
    <PMID>22285168</PMID>
  </reference>
  <reference>
    <citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.</citation>
    <PMID>20573926</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Osimertinib</keyword>
  <keyword>EGFR T790M</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

